[
  {
    "title": "广生堂：拟定增募资不超9.48亿元 用于新冠口服药GST-HG171等临床研究",
    "href": "http://stock.jrj.com.cn/2023/01/06194437265240.shtml",
    "datetime": "2023-01-06 19:44:42",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：创新药控股子公司广生中霖拟增资扩股暨引入投资者",
    "href": "http://stock.jrj.com.cn/2023/01/06194037265301.shtml",
    "datetime": "2023-01-06 19:40:21",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)拟定增募资不超9.48亿元、用于创新药研发项目等",
    "href": "http://stock.jrj.com.cn/2023/01/06193637265226.shtml",
    "datetime": "2023-01-06 19:36:39",
    "code": "300436"
  },
  {
    "title": "A股异动 | 广生堂涨8% 一类广谱抗新冠口服小分子创新药GST-HG171关键性注册临床试验首例受试者入组",
    "href": "http://stock.jrj.com.cn/2022/12/22094237230485.shtml",
    "datetime": "2022-12-22 09:42:55",
    "code": "300436"
  },
  {
    "title": "广生堂：一类广谱抗新冠口服小分子创新药GST-HG171关键性注册临床试验首例受试者入组",
    "href": "http://stock.jrj.com.cn/2022/12/21194837229365.shtml",
    "datetime": "2022-12-21 19:48:52",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：一类广谱抗新冠口服小分子创新药GST-HG171关键性注册临床试验首例受试者入组",
    "href": "http://stock.jrj.com.cn/2022/12/21194637229375.shtml",
    "datetime": "2022-12-21 19:46:47",
    "code": "300436"
  },
  {
    "title": "【龙虎榜】广生堂12月16日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/12/16180137218756.shtml",
    "datetime": "2022-12-16 18:01:34",
    "code": "300436"
  },
  {
    "title": "新冠口服药进入Ⅱ/Ⅲ期临床，广生堂涨停",
    "href": "http://stock.jrj.com.cn/2022/12/16112737217536.shtml",
    "datetime": "2022-12-16 11:27:51",
    "code": "300436"
  },
  {
    "title": "A股异动 | 广生堂涨停 新冠口服药进入II/III期临床",
    "href": "http://stock.jrj.com.cn/2022/12/16095637217251.shtml",
    "datetime": "2022-12-16 09:56:53",
    "code": "300436"
  },
  {
    "title": "获得伦理审查批件 广生堂GST-HG171项目II/III期无缝设计关键性注册临床研究全面实质启动",
    "href": "http://stock.jrj.com.cn/2022/12/15104337214327.shtml",
    "datetime": "2022-12-15 10:43:22",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：一类广谱抗新冠口服小分子创新药GST-HG171获得关键性注册临床试验组长单位伦理审查批件",
    "href": "http://stock.jrj.com.cn/2022/12/15075837213837.shtml",
    "datetime": "2022-12-15 07:58:15",
    "code": "300436"
  },
  {
    "title": "A股异动 | 广生堂涨4% 新冠口服药GST-HG171片I期临床试验达到预期目的",
    "href": "http://stock.jrj.com.cn/2022/12/12095337204635.shtml",
    "datetime": "2022-12-12 09:53:43",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：抗新冠口服药I期临床试验达到试验预期目的",
    "href": "http://stock.jrj.com.cn/2022/12/11170037203925.shtml",
    "datetime": "2022-12-11 17:00:30",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：控股股东非公开发行可交换债券获深交所无异议函",
    "href": "http://stock.jrj.com.cn/2022/11/25183937167684.shtml",
    "datetime": "2022-11-25 18:39:16",
    "code": "300436"
  },
  {
    "title": "广生堂：新冠口服药GST-HG171的IIT研究获伦理委员会批准",
    "href": "http://stock.jrj.com.cn/2022/11/18182537150778.shtml",
    "datetime": "2022-11-18 18:25:35",
    "code": "300436"
  },
  {
    "title": "A股异动 | 广生堂涨17% 部分在研创新药获得专利证书或授权通知书",
    "href": "http://stock.jrj.com.cn/2022/11/11104737130317.shtml",
    "datetime": "2022-11-11 10:47:37",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：部分在研创新药获得专利证书或授权通知书",
    "href": "http://stock.jrj.com.cn/2022/11/10184537128548.shtml",
    "datetime": "2022-11-10 18:45:00",
    "code": "300436"
  },
  {
    "title": "广生堂2022年前三季度亏损7149.31万同比亏损增加 创新药支出大幅增加",
    "href": "http://stock.jrj.com.cn/2022/10/24191137078996.shtml",
    "datetime": "2022-10-24 19:11:54",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)第三季度净亏损4527.05万元",
    "href": "http://stock.jrj.com.cn/2022/10/24170637078349.shtml",
    "datetime": "2022-10-24 17:06:40",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：枸橼酸西地那非片增加50mg规格获批",
    "href": "http://stock.jrj.com.cn/2022/10/21114637072747.shtml",
    "datetime": "2022-10-21 11:46:55",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：一类广谱抗新冠口服小分子创新药GST-HG171片I期临床试验首例受试者成功入组",
    "href": "http://stock.jrj.com.cn/2022/10/09170337041803.shtml",
    "datetime": "2022-10-09 17:03:25",
    "code": "300436"
  },
  {
    "title": "A股异动 | 广生堂涨5% 新冠口服药临床试验获批将具备6000万人份产能",
    "href": "http://stock.jrj.com.cn/2022/09/26094437020358.shtml",
    "datetime": "2022-09-26 09:44:32",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：一类广谱抗新冠口服小分子创新药GST-HG171获批开展临床试验",
    "href": "http://stock.jrj.com.cn/2022/09/25175237019521.shtml",
    "datetime": "2022-09-25 17:52:17",
    "code": "300436"
  },
  {
    "title": "广生堂：新冠口服药GST-HG171获得临床试验批准通知书",
    "href": "http://stock.jrj.com.cn/2022/09/25173837019482.shtml",
    "datetime": "2022-09-25 17:38:30",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：控股股东质押690万股",
    "href": "http://stock.jrj.com.cn/2022/09/15162636997303.shtml",
    "datetime": "2022-09-15 16:26:05",
    "code": "300436"
  },
  {
    "title": "广生堂控股股东奥华集团质押921万股 用于融资",
    "href": "http://stock.jrj.com.cn/2022/08/04205136871494.shtml",
    "datetime": "2022-08-04 20:51:07",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：控股股东质押921万股",
    "href": "http://stock.jrj.com.cn/2022/08/04154836870229.shtml",
    "datetime": "2022-08-04 15:48:11",
    "code": "300436"
  },
  {
    "title": "广生堂：2022年半年实现营收1.93亿元，同比增长11.07%",
    "href": "http://stock.jrj.com.cn/2022/07/28140236850126.shtml",
    "datetime": "2022-07-28 14:02:46",
    "code": "300436"
  },
  {
    "title": "广生堂2022年上半年亏损2622.26万同比亏损增加 研发投入大幅增加",
    "href": "http://stock.jrj.com.cn/2022/07/27223136848445.shtml",
    "datetime": "2022-07-27 22:31:15",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：拟增加经营范围“药品互联网信息服务”、以办理互联网药品信息服务资格证书",
    "href": "http://stock.jrj.com.cn/2022/07/27194436848014.shtml",
    "datetime": "2022-07-27 19:44:12",
    "code": "300436"
  },
  {
    "title": "研发费用大幅增加 广生堂(300436.SZ)上半年净亏损2622.26万元",
    "href": "http://stock.jrj.com.cn/2022/07/27190636847852.shtml",
    "datetime": "2022-07-27 19:06:08",
    "code": "300436"
  },
  {
    "title": "广生堂：乙肝治疗创新药GST-HG121的I期临床试验首例受试者成功入组",
    "href": "http://stock.jrj.com.cn/2022/07/26135136843439.shtml",
    "datetime": "2022-07-26 13:51:29",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：乙肝治疗全球创新药GST-HG121的Ⅰ期临床试验首例受试者成功入组",
    "href": "http://stock.jrj.com.cn/2022/07/26114536843077.shtml",
    "datetime": "2022-07-26 11:45:56",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：乙肝治疗全球创新药GST-HG121获得I期临床试验伦理委员会批件",
    "href": "http://stock.jrj.com.cn/2022/06/24174836757268.shtml",
    "datetime": "2022-06-24 17:48:24",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：在研创新药获得专利证书或授权通知书",
    "href": "http://stock.jrj.com.cn/2022/06/13180036724900.shtml",
    "datetime": "2022-06-13 18:00:53",
    "code": "300436"
  },
  {
    "title": "广生堂股东李国平减持305.4万股 套现1.02亿 2021年公司亏损3488.66万",
    "href": "http://stock.jrj.com.cn/2022/06/10211336720702.shtml",
    "datetime": "2022-06-10 21:13:09",
    "code": "300436"
  },
  {
    "title": "广生堂：实控人减持计划期限已届满 共减持305.4万股公司股份",
    "href": "http://stock.jrj.com.cn/2022/06/10183036720162.shtml",
    "datetime": "2022-06-10 18:30:03",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：减持期届满 实控人李国平已减持1.92%股份",
    "href": "http://stock.jrj.com.cn/2022/06/10175536719936.shtml",
    "datetime": "2022-06-10 17:55:57",
    "code": "300436"
  },
  {
    "title": "广生堂2022年第一季度亏损913.16万同比由盈转亏 研发投入增加",
    "href": "http://stock.jrj.com.cn/2022/04/24161236447670.shtml",
    "datetime": "2022-04-24 16:12:28",
    "code": "300436"
  },
  {
    "title": "广生堂2021年亏损3488.66万同比由盈转亏 董事长李国平薪酬10万",
    "href": "http://stock.jrj.com.cn/2022/04/22195136431093.shtml",
    "datetime": "2022-04-22 19:51:32",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)一季度净亏损913.16万元 同比转亏",
    "href": "http://stock.jrj.com.cn/2022/04/22080336425583.shtml",
    "datetime": "2022-04-22 08:03:30",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)2021年度净亏损3488.66万元 同比转亏",
    "href": "http://stock.jrj.com.cn/2022/04/22080036425584.shtml",
    "datetime": "2022-04-22 08:00:33",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：久哥他达拉非片获得药品批准文号",
    "href": "http://stock.jrj.com.cn/2022/04/13180236325431.shtml",
    "datetime": "2022-04-13 18:02:34",
    "code": "300436"
  },
  {
    "title": "广生堂3名高管合计增持2.24万股 耗资90.86万 2021年公司亏损3000万-4500万",
    "href": "http://stock.jrj.com.cn/2022/03/18193034846744.shtml",
    "datetime": "2022-03-18 19:30:48",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：管理层已完成增持 增持合计2.24万股",
    "href": "http://stock.jrj.com.cn/2022/03/18165434845576.shtml",
    "datetime": "2022-03-18 16:54:56",
    "code": "300436"
  },
  {
    "title": "A股异动 | 广生堂盘中涨停 乙肝治疗创新药GST-HG141临床Ib期试验获得积极结果",
    "href": "http://stock.jrj.com.cn/2022/03/15140634828599.shtml",
    "datetime": "2022-03-15 14:06:56",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：乙肝治疗创新药GST-HG141获得Ib期临床试验初步结果",
    "href": "http://stock.jrj.com.cn/2022/03/14175034824760.shtml",
    "datetime": "2022-03-14 17:50:15",
    "code": "300436"
  },
  {
    "title": "广生堂：乙肝治疗创新药GST-HG141临床Ib期试验获得积极结果",
    "href": "http://stock.jrj.com.cn/2022/03/14174534824679.shtml",
    "datetime": "2022-03-14 17:45:30",
    "code": "300436"
  },
  {
    "title": "广生堂：控股子公司新药GST-HG151的Ⅰ期临床试验首例受试者成功入组",
    "href": "http://stock.jrj.com.cn/2022/03/11133934813356.shtml",
    "datetime": "2022-03-11 13:39:47",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：非酒精性脂肪性肝炎及肝纤维化治疗新药GST-HG151的Ⅰ期临床试验首例受试者成功入组",
    "href": "http://stock.jrj.com.cn/2022/03/11114634813033.shtml",
    "datetime": "2022-03-11 11:46:35",
    "code": "300436"
  },
  {
    "title": "【龙虎榜】广生堂3月10日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/03/10180034810014.shtml",
    "datetime": "2022-03-10 18:00:29",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：使用募集资金4000万元对金塘药业增资以实施募投项目",
    "href": "http://stock.jrj.com.cn/2022/03/09193034599332.shtml",
    "datetime": "2022-03-09 19:30:26",
    "code": "300436"
  },
  {
    "title": "A股异动 | 广生堂(300436.SZ)涨超6% 两个在研创新药获得专利授权通知书",
    "href": "http://stock.jrj.com.cn/2022/03/03104334515194.shtml",
    "datetime": "2022-03-03 10:43:16",
    "code": "300436"
  },
  {
    "title": "广生堂副总经理黄林川辞职 2021年公司亏损3000万-4500万",
    "href": "http://stock.jrj.com.cn/2022/03/02193034513266.shtml",
    "datetime": "2022-03-02 19:30:36",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：两个在研创新药获得专利授权通知书",
    "href": "http://stock.jrj.com.cn/2022/03/02173934512756.shtml",
    "datetime": "2022-03-02 17:39:26",
    "code": "300436"
  },
  {
    "title": "广生堂聘任张玉华担任公司控股子公司广生中霖总经理 2021年公司亏损3000万-4500万",
    "href": "http://stock.jrj.com.cn/2022/02/23215134447956.shtml",
    "datetime": "2022-02-23 21:51:10",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：聘任张玉华为广生中霖总经理",
    "href": "http://stock.jrj.com.cn/2022/02/23160834447476.shtml",
    "datetime": "2022-02-23 16:08:15",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：拟对部分研发项目开发支出转费用化处理和对部分资产计提资产减值准备 合计939.07万元",
    "href": "http://stock.jrj.com.cn/2022/02/16215534374684.shtml",
    "datetime": "2022-02-16 21:55:09",
    "code": "300436"
  },
  {
    "title": "A股异动 | 广生堂涨5% 获董事、高管增持0.85万股",
    "href": "http://stock.jrj.com.cn/2022/02/14141934344239.shtml",
    "datetime": "2022-02-14 14:19:14",
    "code": "300436"
  },
  {
    "title": "广生堂董事、高管李洪明增持股份0.85万股 成交均价34.82元",
    "href": "http://stock.jrj.com.cn/2022/02/11153134323389.shtml",
    "datetime": "2022-02-11 15:31:50",
    "code": "300436"
  },
  {
    "title": "广生堂2021年预计亏损3000万-4500万 同比由盈转亏 药品价格下降",
    "href": "http://stock.jrj.com.cn/2022/01/29175334257646.shtml",
    "datetime": "2022-01-29 17:53:04",
    "code": "300436"
  },
  {
    "title": "【龙虎榜】广生堂1月18日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/01/18180134170441.shtml",
    "datetime": "2022-01-18 18:01:54",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：两个在研创新药获得多地专利授权",
    "href": "http://stock.jrj.com.cn/2022/01/18173634170263.shtml",
    "datetime": "2022-01-18 17:36:32",
    "code": "300436"
  },
  {
    "title": "A股异动丨广生堂(300436.SZ)大跌逾14% 澄清称抗新冠病毒小分子口服药尚处于临床前研究阶段",
    "href": "http://stock.jrj.com.cn/2022/01/18102234168530.shtml",
    "datetime": "2022-01-18 10:22:31",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：抗新冠病毒小分子口服药尚处于临床前研究阶段",
    "href": "http://stock.jrj.com.cn/2022/01/17234134166920.shtml",
    "datetime": "2022-01-17 23:41:31",
    "code": "300436"
  },
  {
    "title": "广生堂：抗新冠病毒小分子口服药尚处于临床前研究阶段",
    "href": "http://stock.jrj.com.cn/2022/01/17201434166035.shtml",
    "datetime": "2022-01-17 20:14:18",
    "code": "300436"
  },
  {
    "title": "【龙虎榜】广生堂1月17日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/01/17180134165418.shtml",
    "datetime": "2022-01-17 18:01:34",
    "code": "300436"
  },
  {
    "title": "A股异动 | 广生堂跌逾5% 实控人已大宗交易减持1.27%股份",
    "href": "http://stock.jrj.com.cn/2022/01/13110634153177.shtml",
    "datetime": "2022-01-13 11:06:35",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：实际控制人李国平已大宗交易减持1.27%股份",
    "href": "http://stock.jrj.com.cn/2022/01/12175734150620.shtml",
    "datetime": "2022-01-12 17:57:43",
    "code": "300436"
  },
  {
    "title": "广生堂回复关注函：3CL蛋白酶抑制剂尚处于临床前研究阶段",
    "href": "http://stock.jrj.com.cn/2021/12/31200134094434.shtml",
    "datetime": "2021-12-31 20:01:59",
    "code": "300436"
  },
  {
    "title": "广生堂回复关注函：3CL蛋白酶抑制剂尚处于临床前研究阶段",
    "href": "http://stock.jrj.com.cn/2021/12/31195734094392.shtml",
    "datetime": "2021-12-31 19:57:33",
    "code": "300436"
  },
  {
    "title": "广生堂：3CL蛋白酶抑制剂研究项目尚处临床前研发阶段",
    "href": "http://stock.jrj.com.cn/2021/12/27192334072064.shtml",
    "datetime": "2021-12-27 19:23:16",
    "code": "300436"
  },
  {
    "title": "两连板广生堂：3CL蛋白酶抑制剂研究项目尚处于临床前研发阶段",
    "href": "http://stock.jrj.com.cn/2021/12/27185834071958.shtml",
    "datetime": "2021-12-27 18:58:26",
    "code": "300436"
  },
  {
    "title": "【龙虎榜】广生堂12月27日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/12/27180034071592.shtml",
    "datetime": "2021-12-27 18:00:44",
    "code": "300436"
  },
  {
    "title": "广生堂控股子公司与药明康德签订抗新型冠状病毒小分子口服药3CL蛋白酶抑制剂合作开发合同书",
    "href": "http://stock.jrj.com.cn/2021/12/24195034059305.shtml",
    "datetime": "2021-12-24 19:50:53",
    "code": "300436"
  },
  {
    "title": "【龙虎榜】广生堂12月24日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/12/24180134058787.shtml",
    "datetime": "2021-12-24 18:01:12",
    "code": "300436"
  },
  {
    "title": "广生堂：控股子公司签订合作开发合同 将进一步丰富公司在抗病毒药物领域布局",
    "href": "http://stock.jrj.com.cn/2021/12/24134534057152.shtml",
    "datetime": "2021-12-24 13:45:03",
    "code": "300436"
  },
  {
    "title": "A股异动 | 广生堂(300436.SZ)午后直线涨停 控股子公司与上海药明康德合作开发抗新冠病毒小分子口服药",
    "href": "http://stock.jrj.com.cn/2021/12/24131634057069.shtml",
    "datetime": "2021-12-24 13:16:44",
    "code": "300436"
  },
  {
    "title": "广生堂控股子公司与上海药明康德合作开发抗新冠病毒小分子口服药",
    "href": "http://stock.jrj.com.cn/2021/12/24123034056952.shtml",
    "datetime": "2021-12-24 12:30:26",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：广生中霖与上海药明康德签订3CL蛋白酶抑制剂合作开发合同书",
    "href": "http://stock.jrj.com.cn/2021/12/24115434056856.shtml",
    "datetime": "2021-12-24 11:54:14",
    "code": "300436"
  },
  {
    "title": "广生堂：与瑞泰来医药签订战略合作框架协议 将开展以包芯片为主高端制剂技术研发合作",
    "href": "http://stock.jrj.com.cn/2021/12/08141133984634.shtml",
    "datetime": "2021-12-08 14:11:48",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)与瑞泰来达成战略合作伙伴关系 将聚焦抢仿药、首仿药、高端难仿药的开发和产业化",
    "href": "http://stock.jrj.com.cn/2021/12/08115533984285.shtml",
    "datetime": "2021-12-08 11:55:31",
    "code": "300436"
  },
  {
    "title": "广生堂：实控人之一李国平拟减持不超2%公司股份",
    "href": "http://stock.jrj.com.cn/2021/12/06200333975421.shtml",
    "datetime": "2021-12-06 20:03:39",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：实控人李国平拟大宗交易减持不超2%股份",
    "href": "http://stock.jrj.com.cn/2021/12/06174333974358.shtml",
    "datetime": "2021-12-06 17:43:34",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：近日收到政府补贴与奖励189万元",
    "href": "http://stock.jrj.com.cn/2021/12/02182633956261.shtml",
    "datetime": "2021-12-02 18:26:16",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：c-Met靶向新药GST-HG161临床研究正在进行Ib期(剂量扩展阶段)试验",
    "href": "http://stock.jrj.com.cn/2021/11/22172233904440.shtml",
    "datetime": "2021-11-22 17:22:03",
    "code": "300436"
  },
  {
    "title": "新药能否“救主”？广生堂研发投入一年比年少 业绩原地踏步",
    "href": "http://stock.jrj.com.cn/2021/11/22083933902226.shtml",
    "datetime": "2021-11-22 08:39:00",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：在研创新药获得专利证书或授权通知书",
    "href": "http://stock.jrj.com.cn/2021/11/18172933873121.shtml",
    "datetime": "2021-11-18 17:29:07",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：3名管理层拟合计增持不低于90万元股份",
    "href": "http://stock.jrj.com.cn/2021/10/22162733733392.shtml",
    "datetime": "2021-10-22 16:27:53",
    "code": "300436"
  },
  {
    "title": "广生堂2021年前三季度预计亏损0.19亿元–0.21亿元 同比由盈转亏",
    "href": "http://stock.jrj.com.cn/2021/10/15163433698785.shtml",
    "datetime": "2021-10-15 16:34:48",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：前三季度预亏1900万元-2100万元",
    "href": "http://stock.jrj.com.cn/2021/10/15154733698499.shtml",
    "datetime": "2021-10-15 15:47:55",
    "code": "300436"
  },
  {
    "title": "广生堂副总经理于舟辞职 2020年薪酬为86.52万",
    "href": "http://stock.jrj.com.cn/2021/09/30193033544562.shtml",
    "datetime": "2021-09-30 19:30:00",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：奥华集团质押400万股、李国平解押400万股",
    "href": "http://stock.jrj.com.cn/2021/09/16180733446135.shtml",
    "datetime": "2021-09-16 18:07:12",
    "code": "300436"
  },
  {
    "title": "广生堂股东奥泰投资减持210万股 套现约7200.54万 上半年公司亏损1709.75万",
    "href": "http://stock.jrj.com.cn/2021/09/06223933394735.shtml",
    "datetime": "2021-09-06 22:39:16",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：福建平潭奥泰科技投资中心以集中竞价减持210万股",
    "href": "http://stock.jrj.com.cn/2021/09/06190633393629.shtml",
    "datetime": "2021-09-06 19:06:11",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：上半年净亏损1709.75万元",
    "href": "http://stock.jrj.com.cn/2021/08/25213233319061.shtml",
    "datetime": "2021-08-25 21:32:34",
    "code": "300436"
  },
  {
    "title": "广生堂2021年半年度亏损1709.75万元 同比由盈转亏",
    "href": "http://stock.jrj.com.cn/2021/08/25210233318900.shtml",
    "datetime": "2021-08-25 21:02:58",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：乙肝治疗创新药GST-HG141的Ib期临床试验首例患者成功入组",
    "href": "http://stock.jrj.com.cn/2021/07/23193333141563.shtml",
    "datetime": "2021-07-23 19:33:46",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：在研创新药获得专利授权通知书",
    "href": "http://stock.jrj.com.cn/2021/07/19163333119428.shtml",
    "datetime": "2021-07-19 16:33:54",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：乙肝治疗创新药GST-HG141获得Ia期临床研究总结报告",
    "href": "http://stock.jrj.com.cn/2021/07/15192733103186.shtml",
    "datetime": "2021-07-15 19:27:40",
    "code": "300436"
  },
  {
    "title": "广生堂2021年上半年预计亏损1600万–1800万由盈转亏 研发费用增加",
    "href": "http://stock.jrj.com.cn/2021/07/14215033096877.shtml",
    "datetime": "2021-07-14 21:50:13",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)半年度预亏1600万-1800万元",
    "href": "http://stock.jrj.com.cn/2021/07/14180233095669.shtml",
    "datetime": "2021-07-14 18:02:09",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：定增发行新增股份1877.7万股将于7月9日上市",
    "href": "http://stock.jrj.com.cn/2021/07/06201333054373.shtml",
    "datetime": "2021-07-06 20:13:27",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：拟使用募集资金向子公司增资以实施募投项目",
    "href": "http://stock.jrj.com.cn/2021/07/05212733049197.shtml",
    "datetime": "2021-07-05 21:27:23",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：成为匹伐他汀钙片上市许可持有人",
    "href": "http://stock.jrj.com.cn/2021/06/30174033022430.shtml",
    "datetime": "2021-06-30 17:40:51",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：成为利伐沙班上市许可持有人",
    "href": "http://stock.jrj.com.cn/2021/06/28171233010630.shtml",
    "datetime": "2021-06-28 17:12:14",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)披露定增结果：宁德市国有资产投资经营获配547.4452万股",
    "href": "http://stock.jrj.com.cn/2021/06/25215032998596.shtml",
    "datetime": "2021-06-25 21:50:08",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：利伐沙班片拟中标第五轮国家集采",
    "href": "http://stock.jrj.com.cn/2021/06/24173432990388.shtml",
    "datetime": "2021-06-24 17:34:38",
    "code": "300436"
  },
  {
    "title": "广生堂：公司积极推动几款新获批仿制药上市销售为公司创造新的利润",
    "href": "http://stock.jrj.com.cn/2021/06/15120832933624.shtml",
    "datetime": "2021-06-15 12:08:55",
    "code": "300436"
  },
  {
    "title": "广生堂：乙肝核心蛋白抑制剂GST-HG141已完成Ia期临床试验",
    "href": "http://stock.jrj.com.cn/2021/06/09115732898843.shtml",
    "datetime": "2021-06-09 11:57:58",
    "code": "300436"
  },
  {
    "title": "广生堂：公司已转让阿吉安（北京）基因科技有限公司 终止长乐和睦家广生妇儿医院建设项目",
    "href": "http://stock.jrj.com.cn/2021/06/02184832864755.shtml",
    "datetime": "2021-06-02 18:48:16",
    "code": "300436"
  },
  {
    "title": "广生堂：公司恩替卡韦片、利伐沙班片已完成上市前工作准备",
    "href": "http://stock.jrj.com.cn/2021/06/02171632863934.shtml",
    "datetime": "2021-06-02 17:16:28",
    "code": "300436"
  },
  {
    "title": "广生堂：GST-HG141是公司乙肝临床治愈“登峰计划”重要组成药物之一 已完成Ia期临床试验",
    "href": "http://stock.jrj.com.cn/2021/05/27171832830582.shtml",
    "datetime": "2021-05-27 17:18:17",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：奥泰投资累计减持1%股份",
    "href": "http://stock.jrj.com.cn/2021/05/17195932771023.shtml",
    "datetime": "2021-05-17 19:59:23",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：奥泰投资已减持0.96%的股份",
    "href": "http://stock.jrj.com.cn/2021/05/13183632749600.shtml",
    "datetime": "2021-05-13 18:36:20",
    "code": "300436"
  },
  {
    "title": "广生堂：泰甘定丙酚替诺福韦片获得药品生产注册证书 有助于进一步完善公司肝病产品管线",
    "href": "http://stock.jrj.com.cn/2021/04/23143832429936.shtml",
    "datetime": "2021-04-23 14:38:29",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：泰甘定丙酚替诺福韦片获批上市",
    "href": "http://stock.jrj.com.cn/2021/04/23120132429369.shtml",
    "datetime": "2021-04-23 12:01:03",
    "code": "300436"
  },
  {
    "title": "广生堂：公司本次再融资将进一步丰富公司产品种类",
    "href": "http://stock.jrj.com.cn/2021/04/22162932423590.shtml",
    "datetime": "2021-04-22 16:29:38",
    "code": "300436"
  },
  {
    "title": "广生堂：枸橼酸西地那非片获药品生产注册证书 将为公司提供新的利润增长点",
    "href": "http://stock.jrj.com.cn/2021/04/16143932386239.shtml",
    "datetime": "2021-04-16 14:39:55",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：劲哥枸橼酸西地那非片获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/04/16120132385544.shtml",
    "datetime": "2021-04-16 12:01:31",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)成为利伐沙班上市许可持有人",
    "href": "http://stock.jrj.com.cn/2021/04/15121532378559.shtml",
    "datetime": "2021-04-15 12:15:24",
    "code": "300436"
  },
  {
    "title": "广生堂2021年第一季度净利减少3.51% 投资收益增加",
    "href": "http://stock.jrj.com.cn/2021/04/13160232365062.shtml",
    "datetime": "2021-04-13 16:02:00",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)一季度净利润降3.51%至177.01万元",
    "href": "http://stock.jrj.com.cn/2021/04/12223732360087.shtml",
    "datetime": "2021-04-12 22:37:50",
    "code": "300436"
  },
  {
    "title": "广生堂：目前尚未确定II期临床试验项目负责人",
    "href": "http://stock.jrj.com.cn/2021/04/08091332330056.shtml",
    "datetime": "2021-04-08 09:13:53",
    "code": "300436"
  },
  {
    "title": "广生堂：GST-HG161 已完成 60～900mg 共 7 个剂量组的耐受性和安全性观察",
    "href": "http://stock.jrj.com.cn/2021/04/08091032330045.shtml",
    "datetime": "2021-04-08 09:10:21",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：乙肝治疗创新药GST-HG141获得Ib期临床试验伦理委员会批件",
    "href": "http://stock.jrj.com.cn/2021/04/02170232271032.shtml",
    "datetime": "2021-04-02 17:02:26",
    "code": "300436"
  },
  {
    "title": "广生堂2020年净利增长38.01% 董事长李国平薪酬4万",
    "href": "http://stock.jrj.com.cn/2021/04/01135232262361.shtml",
    "datetime": "2021-04-01 13:52:08",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：2020年度净利升38.01%至1482.45万元",
    "href": "http://stock.jrj.com.cn/2021/03/31220332258729.shtml",
    "datetime": "2021-03-31 22:03:20",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：恩替卡韦片获批上市",
    "href": "http://stock.jrj.com.cn/2021/03/25183032217301.shtml",
    "datetime": "2021-03-25 18:30:21",
    "code": "300436"
  },
  {
    "title": "广生堂：公司利用自筹资金对募投项目进行先期投入",
    "href": "http://stock.jrj.com.cn/2021/03/25155432215900.shtml",
    "datetime": "2021-03-25 15:54:11",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：奥泰投资拟减持公司不超1.5%股份",
    "href": "http://stock.jrj.com.cn/2021/03/21163832178604.shtml",
    "datetime": "2021-03-21 16:38:04",
    "code": "300436"
  },
  {
    "title": "广生堂：目前公司正在筹备GST-HG161的Ib/II期临床试验",
    "href": "http://stock.jrj.com.cn/2021/03/03153132063620.shtml",
    "datetime": "2021-03-03 15:31:05",
    "code": "300436"
  },
  {
    "title": "广生堂：五款创新药的全球知识产权归广生堂所有",
    "href": "http://stock.jrj.com.cn/2021/03/03152932063606.shtml",
    "datetime": "2021-03-03 15:29:09",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：控股股东与实控人解押及再质押700万股",
    "href": "http://stock.jrj.com.cn/2021/03/02202232059135.shtml",
    "datetime": "2021-03-02 20:22:25",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：五种在研创新药获得专利证书或授权通知书",
    "href": "http://stock.jrj.com.cn/2021/02/22174532006821.shtml",
    "datetime": "2021-02-22 17:45:05",
    "code": "300436"
  },
  {
    "title": "广生堂：公司已着手筹备GST-HG161的Ib/II期临床方案",
    "href": "http://stock.jrj.com.cn/2021/02/20164431997742.shtml",
    "datetime": "2021-02-20 16:44:52",
    "code": "300436"
  },
  {
    "title": "广生堂：索磷布韦片、TAF（富马酸丙酚替诺福韦）、他达拉非片处于排队待审评状态",
    "href": "http://stock.jrj.com.cn/2021/02/20163931997736.shtml",
    "datetime": "2021-02-20 16:39:32",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：GST-HG141已完成Ia期临床试验暨确定泰格医药为Ib期临床试验CRO",
    "href": "http://stock.jrj.com.cn/2021/02/19191331993972.shtml",
    "datetime": "2021-02-19 19:13:03",
    "code": "300436"
  },
  {
    "title": "广生堂获得250万元政府补助",
    "href": "http://stock.jrj.com.cn/2021/01/26121531775441.shtml",
    "datetime": "2021-01-26 12:15:57",
    "code": "300436"
  },
  {
    "title": "广生堂：公司TAF等四款仿制药的生产注册申请均已获国家药监局受理",
    "href": "http://stock.jrj.com.cn/2021/01/25161931765779.shtml",
    "datetime": "2021-01-25 16:19:18",
    "code": "300436"
  },
  {
    "title": "广生堂：公司新型肝癌靶向药物GST-HG161的I期临床预设60-900mg共计7个剂量组 进展顺利",
    "href": "http://stock.jrj.com.cn/2021/01/22153631744903.shtml",
    "datetime": "2021-01-22 15:36:13",
    "code": "300436"
  },
  {
    "title": "[广生堂]省委常委、省纪委书记李仰哲莅临广生堂药业调研",
    "href": "http://stock.jrj.com.cn/2021/01/19000031722607.shtml",
    "datetime": "2021-01-19 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂：目前 公司新型肝癌靶向药物GST-HG161的I期临床已爬坡至900mg剂量组",
    "href": "http://stock.jrj.com.cn/2021/01/07165631648597.shtml",
    "datetime": "2021-01-07 16:56:19",
    "code": "300436"
  },
  {
    "title": "[广生堂]广生堂聘任肝病领域知名专家任红教授担任独立董事",
    "href": "http://stock.jrj.com.cn/2021/01/07000031649510.shtml",
    "datetime": "2021-01-07 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：聘任李洪明为公司首席运营官",
    "href": "http://stock.jrj.com.cn/2021/01/06214131643704.shtml",
    "datetime": "2021-01-06 21:41:42",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：累计获得433.4527万元政府补贴与奖励",
    "href": "http://stock.jrj.com.cn/2021/01/06200031643327.shtml",
    "datetime": "2021-01-06 20:00:15",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：下属公司已签订《收回2018挂牌-1号国有建设用地使用权协议》",
    "href": "http://stock.jrj.com.cn/2020/12/25212631572583.shtml",
    "datetime": "2020-12-25 21:26:22",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)与艾德生物签订分子检测与伴随诊断战略合作框架协议及相关附属协议",
    "href": "http://stock.jrj.com.cn/2020/12/25212531572581.shtml",
    "datetime": "2020-12-25 21:25:20",
    "code": "300436"
  },
  {
    "title": "艾德生物(300685.SZ)与广生堂达成靶向药物临床研究合作",
    "href": "http://stock.jrj.com.cn/2020/12/25210431572519.shtml",
    "datetime": "2020-12-25 21:04:48",
    "code": "300436"
  },
  {
    "title": "[广生堂]广生堂与艾德生物达成伴随诊断战略合作",
    "href": "http://stock.jrj.com.cn/2020/12/25000031583353.shtml",
    "datetime": "2020-12-25 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂：公司四款仿制药项目的生产注册申请均已获得国家药监局受理",
    "href": "http://stock.jrj.com.cn/2020/12/22142831544821.shtml",
    "datetime": "2020-12-22 14:28:53",
    "code": "300436"
  },
  {
    "title": "广生堂：公司富马酸丙酚替诺福韦片（TAF）的生产注册申请于2019年11月获得国家药监局受理",
    "href": "http://stock.jrj.com.cn/2020/12/22142731544815.shtml",
    "datetime": "2020-12-22 14:27:54",
    "code": "300436"
  },
  {
    "title": "广生堂：公司已开始筹备II期临床方案",
    "href": "http://stock.jrj.com.cn/2020/12/22142731544814.shtml",
    "datetime": "2020-12-22 14:27:32",
    "code": "300436"
  },
  {
    "title": "广生堂：公司索磷布韦片于2020年5月收到补充研究通知书",
    "href": "http://stock.jrj.com.cn/2020/12/22142531544809.shtml",
    "datetime": "2020-12-22 14:25:58",
    "code": "300436"
  },
  {
    "title": "广生堂：新型肝癌靶向药物GST-HG161已开始筹备II期临床方案",
    "href": "http://stock.jrj.com.cn/2020/12/14153331487314.shtml",
    "datetime": "2020-12-14 15:33:50",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：乙肝治疗创新药GST-HG141获得三件专利授权通知书",
    "href": "http://stock.jrj.com.cn/2020/12/11172531465587.shtml",
    "datetime": "2020-12-11 17:25:35",
    "code": "300436"
  },
  {
    "title": "广生堂：目前 公司五款创新药均已获批临床",
    "href": "http://stock.jrj.com.cn/2020/12/09151931448734.shtml",
    "datetime": "2020-12-09 15:19:52",
    "code": "300436"
  },
  {
    "title": "广生堂：公司新型肝癌靶向药物GST-HG161的I期临床已爬坡至750mg剂量组 进展顺利",
    "href": "http://stock.jrj.com.cn/2020/12/09151931448735.shtml",
    "datetime": "2020-12-09 15:19:36",
    "code": "300436"
  },
  {
    "title": "广生堂：公司将尽快推动TAF等仿制药项目取得进展并提交补充材料",
    "href": "http://stock.jrj.com.cn/2020/12/03165531400877.shtml",
    "datetime": "2020-12-03 16:55:13",
    "code": "300436"
  },
  {
    "title": "广生堂：GST-HG161的I期临床已爬坡至750mg剂量组进展顺利",
    "href": "http://stock.jrj.com.cn/2020/12/03165431400874.shtml",
    "datetime": "2020-12-03 16:54:22",
    "code": "300436"
  },
  {
    "title": "广生堂：公司抗乙肝病毒药物恩替卡韦（恩甘定）和阿德福韦酯（阿甘定）已中标带量采购",
    "href": "http://stock.jrj.com.cn/2020/12/03153631400084.shtml",
    "datetime": "2020-12-03 15:36:14",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：拟终止医院建设项目并由地方政府有偿收回项目用地",
    "href": "http://stock.jrj.com.cn/2020/12/02181331393760.shtml",
    "datetime": "2020-12-02 18:13:06",
    "code": "300436"
  },
  {
    "title": "[广生堂]广生堂药业荣获2020中国“最具发展潜力雇主”",
    "href": "http://stock.jrj.com.cn/2020/11/30000031376523.shtml",
    "datetime": "2020-11-30 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂：公司四款在研仿制药的生产注册申请均已获国家药监局受理",
    "href": "http://stock.jrj.com.cn/2020/11/25172531347017.shtml",
    "datetime": "2020-11-25 17:25:58",
    "code": "300436"
  },
  {
    "title": "[广生堂]福建广生堂药业股份有限公司入选 “2020福建战略性新兴产业企业100强榜单”",
    "href": "http://stock.jrj.com.cn/2020/11/24000031343223.shtml",
    "datetime": "2020-11-24 00:00:00",
    "code": "300436"
  },
  {
    "title": "[广生堂]国家药监局焦红局长调研广生堂药业",
    "href": "http://stock.jrj.com.cn/2020/11/19000031320874.shtml",
    "datetime": "2020-11-19 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂：公司三款乙肝治疗创新药均已获批临床",
    "href": "http://stock.jrj.com.cn/2020/11/12152631267502.shtml",
    "datetime": "2020-11-12 15:26:07",
    "code": "300436"
  },
  {
    "title": "广生堂：公司非酒精性脂肪肝病及肝纤维化可逆转新药GST-HG151已获批临床",
    "href": "http://stock.jrj.com.cn/2020/11/10091131248522.shtml",
    "datetime": "2020-11-10 09:11:38",
    "code": "300436"
  },
  {
    "title": "广生堂：目前新型肝癌靶向药物GST-HG161的I期临床已爬坡至750mg剂量组",
    "href": "http://stock.jrj.com.cn/2020/11/10090431248463.shtml",
    "datetime": "2020-11-10 09:04:31",
    "code": "300436"
  },
  {
    "title": "广生堂：GST-HG161项目Ⅰ期临床试验首例c-MET阳性患者已于2019年7月9日成功入组",
    "href": "http://stock.jrj.com.cn/2020/11/10090431248462.shtml",
    "datetime": "2020-11-10 09:04:15",
    "code": "300436"
  },
  {
    "title": "广生堂2020年前三季度净利1501.30万增长7.05% 投资收益同比增长",
    "href": "http://stock.jrj.com.cn/2020/10/28153531150798.shtml",
    "datetime": "2020-10-28 15:35:53",
    "code": "300436"
  },
  {
    "title": "[广生堂]广生堂3大产品获评“2020中国化学制药行业抗感染类优秀产品品牌”",
    "href": "http://stock.jrj.com.cn/2020/10/14000031051988.shtml",
    "datetime": "2020-10-14 00:00:00",
    "code": "300436"
  },
  {
    "title": "[广生堂]转发:宁德市工业和信息化局关于公布宁德市第二批制造业单项冠军企业(产品)名录的通告",
    "href": "http://stock.jrj.com.cn/2020/10/14000031056921.shtml",
    "datetime": "2020-10-14 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂：公司乙肝治疗创新药GST-HG141和GST-HG131正处于Ia期临床试验阶段 进展顺利",
    "href": "http://stock.jrj.com.cn/2020/10/10171331016172.shtml",
    "datetime": "2020-10-10 17:13:52",
    "code": "300436"
  },
  {
    "title": "广生堂(300436.SZ)：控股股东非公开发行2019年可交换公司债(第二期)将进入换股期",
    "href": "http://stock.jrj.com.cn/2020/09/22171230810362.shtml",
    "datetime": "2020-09-22 17:12:48",
    "code": "300436"
  },
  {
    "title": "广生堂乙肝治疗创新药HBsAg抑制剂GST-HG121获得临床试验批准",
    "href": "http://stock.jrj.com.cn/2020/09/07195230695147.shtml",
    "datetime": "2020-09-07 19:52:20",
    "code": "300436"
  },
  {
    "title": "[广生堂]广生堂聘请Vadim Bichko博士为“乙肝功能治愈登峰计划”创新药研发科学顾问",
    "href": "http://stock.jrj.com.cn/2020/09/01000030651769.shtml",
    "datetime": "2020-09-01 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂：乙肝治疗创新药GST-HG141获得加拿大专利授权通知书",
    "href": "http://stock.jrj.com.cn/2020/08/31203430645904.shtml",
    "datetime": "2020-08-31 20:34:42",
    "code": "300436"
  },
  {
    "title": "[益丰药房]益丰广生堂大药房开展关爱高温劳动者送清凉公益行动",
    "href": "http://stock.jrj.com.cn/2020/08/31000031043836.shtml",
    "datetime": "2020-08-31 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂2020年上半年净利1137.17万增长0.32% 销售费用及管理费用减少",
    "href": "http://stock.jrj.com.cn/2020/08/27221330607147.shtml",
    "datetime": "2020-08-27 22:13:22",
    "code": "300436"
  },
  {
    "title": "[广生堂]副省长林宝金莅临广生堂药业公司考察调研",
    "href": "http://stock.jrj.com.cn/2020/08/14000030499947.shtml",
    "datetime": "2020-08-14 00:00:00",
    "code": "300436"
  },
  {
    "title": "[广生堂]创新共赢,逐梦起航 | 广生堂与上药控股签署战略合作协议",
    "href": "http://stock.jrj.com.cn/2020/08/07000030449221.shtml",
    "datetime": "2020-08-07 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂职工代表监事江妹辞职 2019年薪酬为8.53万元",
    "href": "http://stock.jrj.com.cn/2020/07/17215630276809.shtml",
    "datetime": "2020-07-17 21:56:07",
    "code": "300436"
  },
  {
    "title": "【公告解读】广生堂：乙肝治疗全球创新药GST-HG121临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2020/06/17215629951692.shtml",
    "datetime": "2020-06-17 21:56:41",
    "code": "300436"
  },
  {
    "title": "广生堂：乙肝治疗全球创新药GST-HG121临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2020/06/17172329950311.shtml",
    "datetime": "2020-06-17 17:23:09",
    "code": "300436"
  },
  {
    "title": "广生堂：公司四大抗乙肝病毒药物全线通过仿制药质量与疗效一致性评价",
    "href": "http://stock.jrj.com.cn/2020/06/07174029861532.shtml",
    "datetime": "2020-06-07 17:40:00",
    "code": "300436"
  },
  {
    "title": "广生堂：抗乙肝病毒药物拉米夫定片通过一致性评价",
    "href": "http://stock.jrj.com.cn/2020/06/07163329861302.shtml",
    "datetime": "2020-06-07 16:33:40",
    "code": "300436"
  },
  {
    "title": "广生堂乙肝治疗全球创新药成功入组给药 审批上市尚需系列临床研究",
    "href": "http://stock.jrj.com.cn/invest/2020/05/28130229850833.shtml",
    "datetime": "2020-05-28 13:02:00",
    "code": "300436"
  },
  {
    "title": "广生堂乙肝治疗全球创新药成功入组给药 审批上市尚需系列临床研究",
    "href": "http://stock.jrj.com.cn/invest/2020/05/28130229787600.shtml",
    "datetime": "2020-05-28 13:02:00",
    "code": "300436"
  },
  {
    "title": "午间公告集锦：广生堂乙肝治疗创新药取得重要进展",
    "href": "http://stock.jrj.com.cn/2020/05/28122629786923.shtml",
    "datetime": "2020-05-28 12:26:09",
    "code": "300436"
  },
  {
    "title": "广生堂研发新冠药物未披露安全性 被深交所下发监管函",
    "href": "http://stock.jrj.com.cn/2020/04/27150829395438.shtml",
    "datetime": "2020-04-27 15:08:46",
    "code": "300436"
  },
  {
    "title": "广生堂：乙肝治疗全球创新药GST-HG141获临床试验伦理委员会批件",
    "href": "http://stock.jrj.com.cn/2020/04/23172429359324.shtml",
    "datetime": "2020-04-23 17:24:00",
    "code": "300436"
  },
  {
    "title": "“跨界”研发硫酸羟氯喹？广生堂：临床试验显示对新冠肺炎有疗效",
    "href": "http://stock.jrj.com.cn/2020/04/22185529350666.shtml",
    "datetime": "2020-04-22 18:55:15",
    "code": "300436"
  },
  {
    "title": "归母净利连续四年下滑 广生堂加码创新药能否”救急病“",
    "href": "http://stock.jrj.com.cn/2020/04/22073829344707.shtml",
    "datetime": "2020-04-22 07:38:33",
    "code": "300436"
  },
  {
    "title": "广生堂收关注函 要求说明硫酸羟氯喹与公司主营业务的关联性",
    "href": "http://stock.jrj.com.cn/2020/04/17095829311399.shtml",
    "datetime": "2020-04-17 09:58:00",
    "code": "300436"
  },
  {
    "title": "广生堂收到深交所关注函：要求说明硫酸羟氯喹与公司主营业务的关联性",
    "href": "http://stock.jrj.com.cn/2020/04/17092029310647.shtml",
    "datetime": "2020-04-17 09:20:53",
    "code": "300436"
  },
  {
    "title": "广生堂与北京阳光诺和签订硫酸羟氯喹技术开发合同",
    "href": "http://stock.jrj.com.cn/2020/04/15183629297975.shtml",
    "datetime": "2020-04-15 18:36:44",
    "code": "300436"
  },
  {
    "title": "中西医护航：硫酸羟氯喹或用于治疗新冠肺炎 红日药业血必净获批用于重型、危重型新冠肺炎",
    "href": "http://stock.jrj.com.cn/2020/04/14225629286915.shtml",
    "datetime": "2020-04-14 22:56:07",
    "code": "300436"
  },
  {
    "title": "广生堂：签订硫酸羟氯喹技术开发合同",
    "href": "http://stock.jrj.com.cn/2020/04/14220329286622.shtml",
    "datetime": "2020-04-14 22:03:49",
    "code": "300436"
  },
  {
    "title": "广生堂：拟定增募资不超5.5亿元",
    "href": "http://stock.jrj.com.cn/2020/04/01210329171118.shtml",
    "datetime": "2020-04-01 21:03:20",
    "code": "300436"
  },
  {
    "title": "广生堂：拟定增募资不超5.5亿元 增强药品生产能力",
    "href": "http://stock.jrj.com.cn/2020/04/01204829171044.shtml",
    "datetime": "2020-04-01 20:48:00",
    "code": "300436"
  },
  {
    "title": "净利四连跌 广生堂创新战略何时奏效",
    "href": "http://stock.jrj.com.cn/2020/03/31013329150682.shtml",
    "datetime": "2020-03-31 01:33:55",
    "code": "300436"
  },
  {
    "title": "广生堂：2020年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/03/26023029110087.shtml",
    "datetime": "2020-03-26 02:30:00",
    "code": "300436"
  },
  {
    "title": "广生堂：预计一季度营收净利均同比下降",
    "href": "http://stock.jrj.com.cn/2020/03/25215129109027.shtml",
    "datetime": "2020-03-25 21:51:21",
    "code": "300436"
  },
  {
    "title": "广生堂：2019年年度报告主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/03/25213029108871.shtml",
    "datetime": "2020-03-25 21:30:00",
    "code": "300436"
  },
  {
    "title": "广生堂：一季度营收净利预计均同比下降",
    "href": "http://stock.jrj.com.cn/2020/03/25205529108675.shtml",
    "datetime": "2020-03-25 20:55:00",
    "code": "300436"
  },
  {
    "title": "广生堂：乙肝治疗全球创新药HBsAg抑制剂GST-HG131获准临床试验",
    "href": "http://stock.jrj.com.cn/2020/03/05173928960019.shtml",
    "datetime": "2020-03-05 17:39:00",
    "code": "300436"
  },
  {
    "title": "广生堂：乙肝治疗全球创新药获得临床试验通知书",
    "href": "http://stock.jrj.com.cn/2020/03/05172928959937.shtml",
    "datetime": "2020-03-05 17:29:48",
    "code": "300436"
  },
  {
    "title": "广生堂：中国首个获批临床的乙肝表面抗原抑制剂获得临床试验通知书",
    "href": "http://stock.jrj.com.cn/2020/03/05171528959849.shtml",
    "datetime": "2020-03-05 17:15:17",
    "code": "300436"
  },
  {
    "title": "广生堂：GST-HG131成中国首个获批临床的乙肝表面抗原（HBsAg）抑制剂",
    "href": "http://stock.jrj.com.cn/2020/03/05171328959843.shtml",
    "datetime": "2020-03-05 17:13:00",
    "code": "300436"
  },
  {
    "title": "广生堂2019年盈利1069万元下滑35% 药品价格有所下降",
    "href": "http://stock.jrj.com.cn/2020/02/29131228919451.shtml",
    "datetime": "2020-02-29 13:12:35",
    "code": "300436"
  },
  {
    "title": "广生堂：联营公司指定为福州市开展新冠病毒核酸检测单位",
    "href": "http://stock.jrj.com.cn/2020/02/17180728840092.shtml",
    "datetime": "2020-02-17 18:07:49",
    "code": "300436"
  },
  {
    "title": "广生堂：联营公司被指定为福州市开展新冠病毒核酸检测单位",
    "href": "http://stock.jrj.com.cn/2020/02/17175628840044.shtml",
    "datetime": "2020-02-17 17:56:00",
    "code": "300436"
  },
  {
    "title": "广生堂：子公司产品被列入《临时性纳入挂网采购的新型冠状病毒感染肺炎诊疗有关药品目录》",
    "href": "http://stock.jrj.com.cn/2020/02/14170328830508.shtml",
    "datetime": "2020-02-14 17:03:04",
    "code": "300436"
  },
  {
    "title": "广生堂：子公司产品被列入浙江《临时性纳入挂网采购的新型冠状病毒感染肺炎诊疗有关药",
    "href": "http://stock.jrj.com.cn/2020/02/14164028830389.shtml",
    "datetime": "2020-02-14 16:40:00",
    "code": "300436"
  },
  {
    "title": "广生堂：水飞蓟宾葡甲胺片纳入浙江省治疗新型冠状病毒感染肺炎诊疗药品目录",
    "href": "http://stock.jrj.com.cn/2020/02/14163328830344.shtml",
    "datetime": "2020-02-14 16:33:05",
    "code": "300436"
  },
  {
    "title": "广生堂获抗新型冠状病毒药物临床试验伦理委员会批件",
    "href": "http://stock.jrj.com.cn/2020/02/12230828818091.shtml",
    "datetime": "2020-02-12 23:08:03",
    "code": "300436"
  },
  {
    "title": "广生堂获得抗新型冠状病毒药物临床试验伦理委员会批件",
    "href": "http://stock.jrj.com.cn/2020/02/12171928816423.shtml",
    "datetime": "2020-02-12 17:19:28",
    "code": "300436"
  },
  {
    "title": "广生堂：获抗新型冠状病毒药物临床试验伦理委员会批件",
    "href": "http://stock.jrj.com.cn/2020/02/12170428816339.shtml",
    "datetime": "2020-02-12 17:04:00",
    "code": "300436"
  },
  {
    "title": "广生堂：获得抗新型冠状病毒药物临床试验伦理委员会批件",
    "href": "http://stock.jrj.com.cn/2020/02/12165828816308.shtml",
    "datetime": "2020-02-12 16:58:00",
    "code": "300436"
  },
  {
    "title": "开展抗2019-nCoV 药物研发 广生堂涨停",
    "href": "http://stock.jrj.com.cn/2020/02/11105728808096.shtml",
    "datetime": "2020-02-11 10:57:58",
    "code": "300436"
  },
  {
    "title": "公告精选：多家券商披露1月份经营数据；广生堂开展抗2019-nCoV药物研发",
    "href": "http://stock.jrj.com.cn/2020/02/10210428804820.shtml",
    "datetime": "2020-02-10 21:04:00",
    "code": "300436"
  },
  {
    "title": "广生堂开展抗2019-nCoV药物研发",
    "href": "http://stock.jrj.com.cn/2020/02/10164228803566.shtml",
    "datetime": "2020-02-10 16:42:58",
    "code": "300436"
  },
  {
    "title": "广生堂：开展抗2019-nCoV药物研发",
    "href": "http://stock.jrj.com.cn/2020/02/10164228803563.shtml",
    "datetime": "2020-02-10 16:42:21",
    "code": "300436"
  },
  {
    "title": "广生堂2019年度预计净利800万元-1200万元 同比下降27.20%-51.47%",
    "href": "http://stock.jrj.com.cn/2020/01/22230728723331.shtml",
    "datetime": "2020-01-22 23:07:53",
    "code": "300436"
  },
  {
    "title": "广生堂仿制药阿德福韦酯片拟中标第二批全国药品集中采购",
    "href": "http://stock.jrj.com.cn/2020/01/18102928696296.shtml",
    "datetime": "2020-01-18 10:29:50",
    "code": "300436"
  },
  {
    "title": "广生堂：公司阿德福韦酯拟中标第二批全国药品集中采购",
    "href": "http://stock.jrj.com.cn/2020/01/17180428693724.shtml",
    "datetime": "2020-01-17 18:04:54",
    "code": "300436"
  },
  {
    "title": "广生堂：阿德福韦酯拟中标第二批全国药品集中采购",
    "href": "http://stock.jrj.com.cn/2020/01/17173528693570.shtml",
    "datetime": "2020-01-17 17:35:00",
    "code": "300436"
  },
  {
    "title": "广生堂确定乙肝治疗药GST-HG141临床研究机构和研究负责人",
    "href": "http://stock.jrj.com.cn/2020/01/16131428685969.shtml",
    "datetime": "2020-01-16 13:14:36",
    "code": "300436"
  },
  {
    "title": "[广生堂]福建广生堂药业股份有限公司被授予 “国家企业技术中心”称号",
    "href": "http://stock.jrj.com.cn/2020/01/14000028688133.shtml",
    "datetime": "2020-01-14 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂及控股子公司4月份以来累计获得491万元政府补贴与奖励",
    "href": "http://stock.jrj.com.cn/2019/12/25224828587183.shtml",
    "datetime": "2019-12-25 22:48:34",
    "code": "300436"
  },
  {
    "title": "[广生堂]“抗肝纤维化药物GST-HG151的临床前研究及Ⅰ期临床试验研究” 获2019国家重大新药创制专项立项支持",
    "href": "http://stock.jrj.com.cn/2019/12/24000028580331.shtml",
    "datetime": "2019-12-24 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂：抗肝纤维化药物专项课题列入国家重大新药创制科技重大专项",
    "href": "http://stock.jrj.com.cn/2019/12/23170028573186.shtml",
    "datetime": "2019-12-23 17:00:40",
    "code": "300436"
  },
  {
    "title": "广生堂：全球创新药乙肝表面抗原（HBsAg）抑制剂GST-HG131临床试验申请获得受理",
    "href": "http://stock.jrj.com.cn/2019/12/10170528514374.shtml",
    "datetime": "2019-12-10 17:05:00",
    "code": "300436"
  },
  {
    "title": "广生堂：乙肝治疗全球创新药临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2019/12/10162928514224.shtml",
    "datetime": "2019-12-10 16:29:11",
    "code": "300436"
  },
  {
    "title": "[广生堂]广生堂被确定为2019年省级科技成果产业化基地",
    "href": "http://stock.jrj.com.cn/2019/12/10000028519284.shtml",
    "datetime": "2019-12-10 00:00:00",
    "code": "300436"
  },
  {
    "title": "[广生堂]我司荣获2019中国“最具发展潜力雇主”",
    "href": "http://stock.jrj.com.cn/2019/12/03000028483217.shtml",
    "datetime": "2019-12-03 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂股东叶理青及一致行动人拟减持股份 预计减持不超总股本2.47%",
    "href": "http://stock.jrj.com.cn/2019/11/22131028437492.shtml",
    "datetime": "2019-11-22 13:10:16",
    "code": "300436"
  },
  {
    "title": "广生堂：实控人之一拟减持不超2.47%股份",
    "href": "http://stock.jrj.com.cn/2019/11/21210228434221.shtml",
    "datetime": "2019-11-21 21:02:07",
    "code": "300436"
  },
  {
    "title": "广生堂：实控人之一拟减持公司股份",
    "href": "http://stock.jrj.com.cn/2019/11/21195328433842.shtml",
    "datetime": "2019-11-21 19:53:00",
    "code": "300436"
  },
  {
    "title": "大股东频繁减持 出售子公司“粉饰”业绩 广生堂颓势何时止",
    "href": "http://stock.jrj.com.cn/2019/11/19082828416755.shtml",
    "datetime": "2019-11-19 08:28:00",
    "code": "300436"
  },
  {
    "title": "广生堂2名股东合计减持258万股 套现约1.01亿元",
    "href": "http://stock.jrj.com.cn/2019/11/15112828404039.shtml",
    "datetime": "2019-11-15 11:28:11",
    "code": "300436"
  },
  {
    "title": "广生堂：控股子公司被认定为省级工业企业技术中心",
    "href": "http://stock.jrj.com.cn/2019/11/11171228380604.shtml",
    "datetime": "2019-11-11 17:12:43",
    "code": "300436"
  },
  {
    "title": "广生堂乙肝创新药临床实验获批 将积极开展FDA临床注册申报",
    "href": "http://stock.jrj.com.cn/2019/11/06230428362273.shtml",
    "datetime": "2019-11-06 23:04:00",
    "code": "300436"
  },
  {
    "title": "广生堂：乙肝治疗全球创新药GST-HG141获得临床试验通知书",
    "href": "http://stock.jrj.com.cn/2019/11/06173328360733.shtml",
    "datetime": "2019-11-06 17:33:28",
    "code": "300436"
  },
  {
    "title": "广生堂：乙肝治疗全球创新药GST-HG141获临床试验通知书",
    "href": "http://stock.jrj.com.cn/2019/11/06172828360711.shtml",
    "datetime": "2019-11-06 17:28:41",
    "code": "300436"
  },
  {
    "title": "乙肝患者盼来福音 广生堂申报药品进入生产审评审批阶段",
    "href": "http://stock.jrj.com.cn/2019/11/04202528350131.shtml",
    "datetime": "2019-11-04 20:25:00",
    "code": "300436"
  },
  {
    "title": "广生堂：获得富马酸丙酚替诺福韦片（TAF）生产注册受理通知书",
    "href": "http://stock.jrj.com.cn/2019/11/04164028349038.shtml",
    "datetime": "2019-11-04 16:40:00",
    "code": "300436"
  },
  {
    "title": "广生堂：获得乙肝治疗一线用药富马酸丙酚替诺福韦片生产注册受理通知书",
    "href": "http://stock.jrj.com.cn/2019/11/04163228348979.shtml",
    "datetime": "2019-11-04 16:32:45",
    "code": "300436"
  },
  {
    "title": "广生堂实控人之一拟减持不超1.28%股份",
    "href": "http://stock.jrj.com.cn/2019/10/31183128334629.shtml",
    "datetime": "2019-10-31 18:31:59",
    "code": "300436"
  },
  {
    "title": "广生堂：持股5.36%的股东拟减持不超1.28%股份",
    "href": "http://stock.jrj.com.cn/2019/10/31165728334122.shtml",
    "datetime": "2019-10-31 16:57:49",
    "code": "300436"
  },
  {
    "title": "广生堂：实控人之一拟减持不超1.28%股份",
    "href": "http://stock.jrj.com.cn/2019/10/31165728334127.shtml",
    "datetime": "2019-10-31 16:57:00",
    "code": "300436"
  },
  {
    "title": "广生堂第三季度盈利269万 同比增长58%",
    "href": "http://stock.jrj.com.cn/2019/10/25083728298164.shtml",
    "datetime": "2019-10-25 08:37:27",
    "code": "300436"
  },
  {
    "title": "广生堂前三季度净利润同比增长132%",
    "href": "http://stock.jrj.com.cn/2019/10/24181228295209.shtml",
    "datetime": "2019-10-24 18:12:52",
    "code": "300436"
  },
  {
    "title": "广生堂2019年前三季度净利1350万-1450万 医药行业药价下行",
    "href": "http://stock.jrj.com.cn/2019/10/15093928248041.shtml",
    "datetime": "2019-10-15 09:39:32",
    "code": "300436"
  },
  {
    "title": "广生堂：2019年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/10/14235028245760.shtml",
    "datetime": "2019-10-14 23:50:00",
    "code": "300436"
  },
  {
    "title": "[广生堂]热烈祝贺广生堂药业被评为医药产业标杆企业",
    "href": "http://stock.jrj.com.cn/2019/10/11000028234716.shtml",
    "datetime": "2019-10-11 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂拟中标联合采购背后：抗乙肝病毒药不足两年降价98%",
    "href": "http://stock.jrj.com.cn/2019/09/25164128178913.shtml",
    "datetime": "2019-09-25 16:41:17",
    "code": "300436"
  },
  {
    "title": "广生堂：恩替卡韦拟中标联盟地区药品集中采购",
    "href": "http://stock.jrj.com.cn/2019/09/24201528174285.shtml",
    "datetime": "2019-09-24 20:15:29",
    "code": "300436"
  },
  {
    "title": "广生堂：公司药品恩替卡韦胶囊拟中标联盟地区药品集中采购",
    "href": "http://stock.jrj.com.cn/2019/09/24200928174279.shtml",
    "datetime": "2019-09-24 20:09:00",
    "code": "300436"
  },
  {
    "title": "广生堂实际控制人暨董事长李国平拟减持股份 预计减持不超总股本0.58%",
    "href": "http://stock.jrj.com.cn/2019/09/11075928119209.shtml",
    "datetime": "2019-09-11 07:59:31",
    "code": "300436"
  },
  {
    "title": "广生堂2019年上半年净利1134万 持续对中兴药业进行整合优化",
    "href": "http://stock.jrj.com.cn/2019/08/25180428028805.shtml",
    "datetime": "2019-08-25 18:04:16",
    "code": "300436"
  },
  {
    "title": "广生堂：29个药品被纳入国家医保目录",
    "href": "http://stock.jrj.com.cn/2019/08/22185628018240.shtml",
    "datetime": "2019-08-22 18:56:20",
    "code": "300436"
  },
  {
    "title": "[广生堂]2019年第九届广生堂药业“梦想启航·助力前行”奖助学活动成功举行",
    "href": "http://stock.jrj.com.cn/2019/08/21000028011625.shtml",
    "datetime": "2019-08-21 00:00:00",
    "code": "300436"
  },
  {
    "title": "[广生堂]2019年第九届广生堂药业“梦想启航·助力前行”奖助学活动成功举行",
    "href": "http://stock.jrj.com.cn/2019/08/21000028933255.shtml",
    "datetime": "2019-08-21 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂涨停：新药临床试验获受理 将挑战乙肝功能性治愈",
    "href": "http://stock.jrj.com.cn/2019/08/14151227975484.shtml",
    "datetime": "2019-08-14 15:12:19",
    "code": "300436"
  },
  {
    "title": "乙肝治疗创新药临床试验申请获受理 广生堂涨停",
    "href": "http://stock.jrj.com.cn/2019/08/14134427975155.shtml",
    "datetime": "2019-08-14 13:44:39",
    "code": "300436"
  },
  {
    "title": "午间公告：广生堂乙肝治疗创新药临床试验申请获受理",
    "href": "http://stock.jrj.com.cn/2019/08/14115927974584.shtml",
    "datetime": "2019-08-14 11:59:03",
    "code": "300436"
  },
  {
    "title": "广生堂控股股东非公开发行可交换债券 总额不超过2.3亿元",
    "href": "http://stock.jrj.com.cn/2019/08/07080427941345.shtml",
    "datetime": "2019-08-07 08:04:56",
    "code": "300436"
  },
  {
    "title": "广生堂控股股东股份解除质押270万股",
    "href": "http://stock.jrj.com.cn/2019/08/07080227941329.shtml",
    "datetime": "2019-08-07 08:02:36",
    "code": "300436"
  },
  {
    "title": "冲刺“伟哥”市场未受资金认可 广生堂股价跌停",
    "href": "http://stock.jrj.com.cn/2019/08/05115427929833.shtml",
    "datetime": "2019-08-05 11:54:41",
    "code": "300436"
  },
  {
    "title": "毛利率近90%！国产伟哥要“扩军” 50亿市场再起硝烟",
    "href": "http://stock.jrj.com.cn/2019/07/31185327909786.shtml",
    "datetime": "2019-07-31 18:53:52",
    "code": "300436"
  },
  {
    "title": "又一国产“伟哥”递交注册申请 广生堂称治ED药品市场规模近50亿",
    "href": "http://stock.jrj.com.cn/2019/07/31023727906028.shtml",
    "datetime": "2019-07-31 02:37:20",
    "code": "300436"
  },
  {
    "title": "又一国产“伟哥”递交注册申请 广生堂称ED市场规模近50亿",
    "href": "http://stock.jrj.com.cn/2019/07/30215527905534.shtml",
    "datetime": "2019-07-30 21:55:31",
    "code": "300436"
  },
  {
    "title": "广生堂：枸橼酸西地那非片生产注册申请获受理",
    "href": "http://stock.jrj.com.cn/2019/07/30163927904197.shtml",
    "datetime": "2019-07-30 16:39:50",
    "code": "300436"
  },
  {
    "title": "沐阳：广生堂——乙肝疫苗为何让股价一飞冲天？",
    "href": "http://stock.jrj.com.cn/2019/07/17161727852393.shtml",
    "datetime": "2019-07-17 16:17:08",
    "code": "300436"
  },
  {
    "title": "广生堂：2019年半年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/07/14214027838539.shtml",
    "datetime": "2019-07-14 21:40:01",
    "code": "300436"
  },
  {
    "title": "广生堂2019年上半年盈利1080万元-1200万元 同比增长150%-177%",
    "href": "http://stock.jrj.com.cn/2019/07/14174327838123.shtml",
    "datetime": "2019-07-14 17:43:44",
    "code": "300436"
  },
  {
    "title": "[广生堂]肝癌靶向新药GST-161临床试验首例患者成功入组",
    "href": "http://stock.jrj.com.cn/2019/07/11000027882435.shtml",
    "datetime": "2019-07-11 00:00:00",
    "code": "300436"
  },
  {
    "title": "[广生堂]新型肝癌靶向药物GST-HG161临床试验例患者成功入组",
    "href": "http://stock.jrj.com.cn/2019/07/11000028928733.shtml",
    "datetime": "2019-07-11 00:00:00",
    "code": "300436"
  },
  {
    "title": "[广生堂]新型肝癌靶向药物GST-HG161临床试验首例患者成功入组",
    "href": "http://stock.jrj.com.cn/2019/07/11000028064829.shtml",
    "datetime": "2019-07-11 00:00:00",
    "code": "300436"
  },
  {
    "title": "新型肝癌靶向药物临床试验首例c-MET阳性患者入组成功 广生堂涨停",
    "href": "http://stock.jrj.com.cn/2019/07/10095127820453.shtml",
    "datetime": "2019-07-10 09:51:39",
    "code": "300436"
  },
  {
    "title": "广生堂：新型肝癌靶向药物临床试验首例c-MET阳性患者入组成功",
    "href": "http://stock.jrj.com.cn/2019/07/09155527816836.shtml",
    "datetime": "2019-07-09 15:55:20",
    "code": "300436"
  },
  {
    "title": "广生堂：乙肝治疗全球创新药递交Pre-IND会议申请",
    "href": "http://stock.jrj.com.cn/2019/07/01190827779699.shtml",
    "datetime": "2019-07-01 19:08:26",
    "code": "300436"
  },
  {
    "title": "广生堂：GST-HG131乙肝治疗全球创新药递交Pre-IND会议申请",
    "href": "http://stock.jrj.com.cn/2019/07/01185727779659.shtml",
    "datetime": "2019-07-01 18:57:18",
    "code": "300436"
  },
  {
    "title": "乙肝治疗全新靶点创新药取得新进展 广生堂涨停",
    "href": "http://stock.jrj.com.cn/2019/06/25141227752752.shtml",
    "datetime": "2019-06-25 14:12:26",
    "code": "300436"
  },
  {
    "title": "[广生堂]GST-HG121选定PCC化合物 有望成为全球乙肝治疗全新靶点创新药",
    "href": "http://stock.jrj.com.cn/2019/06/25000027770355.shtml",
    "datetime": "2019-06-25 00:00:00",
    "code": "300436"
  },
  {
    "title": "[广生堂]GST-HG121选定PCC化合物 有望成为全球乙肝治疗全新靶点创新药",
    "href": "http://stock.jrj.com.cn/2019/06/25000028928734.shtml",
    "datetime": "2019-06-25 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂乙肝治疗全球创新药获进展 拟明年开始临床组合研究",
    "href": "http://stock.jrj.com.cn/2019/06/24204127751848.shtml",
    "datetime": "2019-06-24 20:41:00",
    "code": "300436"
  },
  {
    "title": "广生堂：乙肝治疗全新靶点创新药取得新进展",
    "href": "http://stock.jrj.com.cn/2019/06/24184527748825.shtml",
    "datetime": "2019-06-24 18:45:37",
    "code": "300436"
  },
  {
    "title": "广生堂：拟1150万元转让阿吉安北京100%股权",
    "href": "http://stock.jrj.com.cn/2019/06/11184027687680.shtml",
    "datetime": "2019-06-11 18:40:39",
    "code": "300436"
  },
  {
    "title": "广生堂股东李国平质押600万 股公司去年净利同比下滑51%",
    "href": "http://stock.jrj.com.cn/2019/05/06083527527240.shtml",
    "datetime": "2019-05-06 08:35:25",
    "code": "300436"
  },
  {
    "title": "广生堂：抗乙肝病毒药物阿德福韦酯片通过一致性评价",
    "href": "http://stock.jrj.com.cn/2019/04/30180827515359.shtml",
    "datetime": "2019-04-30 18:08:09",
    "code": "300436"
  },
  {
    "title": "广生堂：抗乙肝病毒药物阿德福韦酯片通过一致性评价",
    "href": "http://stock.jrj.com.cn/2019/04/30174727515253.shtml",
    "datetime": "2019-04-30 17:47:54",
    "code": "300436"
  },
  {
    "title": "[广生堂]广生堂全球创新药临床试验获批 有望填补脂肪肝用药空白",
    "href": "http://stock.jrj.com.cn/2019/04/21000027770354.shtml",
    "datetime": "2019-04-21 00:00:00",
    "code": "300436"
  },
  {
    "title": "[广生堂]广生堂全球创新药临床试验获批 有望填补脂肪肝用药空白",
    "href": "http://stock.jrj.com.cn/2019/04/21000028928737.shtml",
    "datetime": "2019-04-21 00:00:00",
    "code": "300436"
  },
  {
    "title": "[广生堂]广生堂药业非酒精性脂肪肝病全球创新药临床试验获批",
    "href": "http://stock.jrj.com.cn/2019/04/20000027770352.shtml",
    "datetime": "2019-04-20 00:00:00",
    "code": "300436"
  },
  {
    "title": "[广生堂]广生堂药业非酒精性脂肪肝病全球创新药临床试验获批",
    "href": "http://stock.jrj.com.cn/2019/04/20000028928736.shtml",
    "datetime": "2019-04-20 00:00:00",
    "code": "300436"
  },
  {
    "title": "广生堂：股东叶理青及一致行动人奥泰投资拟合计减持不超4.96%股份",
    "href": "http://stock.jrj.com.cn/2019/04/18171727423202.shtml",
    "datetime": "2019-04-18 17:17:00",
    "code": "300436"
  },
  {
    "title": "广生堂：一实控人及一致行动人拟合计减持不超过4.96％股份",
    "href": "http://stock.jrj.com.cn/2019/04/18171527423025.shtml",
    "datetime": "2019-04-18 17:15:40",
    "code": "300436"
  }
]